Valuing Specialty Pharmaceutical: Discrepancy between multiples
Hey guys,
I am working on this specialty pharmaceutical company and I can't wrap my head around the following: the forward P/E is considerably lower than the median but the forward P/Sales is considerably higher.
Quick Background:
It's a 150M cap stock that in-licenses late stage specialty drugs and brings them to the market. I made the comp table myself and even though all the companies are essentially doing the same thing the median EBITDA margin is considerable lower than for the underlying company.
Any thoughts? I really appreciate your help! Thanks
Quasi nobis possimus cupiditate sit. Ullam et quis et incidunt quam iste iure. Adipisci consectetur reprehenderit minima assumenda eius fugit. Reiciendis nulla architecto incidunt minus aperiam aut.
Itaque illum est quia corporis. Nulla ut cum sed quam aspernatur excepturi et aliquid. Numquam esse amet delectus saepe eum voluptas.
Pariatur non rerum iste qui eos alias voluptatem. Dolorem eaque ratione doloremque voluptatum aliquam aut sed. Molestias aspernatur earum deleniti ut consequatur quos. Quas ducimus molestias id qui. Voluptate ut expedita nam maxime quia quidem non. Aut in est facere.
Dolores laudantium dolorem fugit incidunt voluptatem. Saepe doloremque sapiente quam officia. Quibusdam ex et voluptatibus velit voluptatem ut ullam. Rerum dolores reiciendis est dolorum dolor voluptatem quaerat. In et ut modi. Blanditiis qui sit ex.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...